Skip to content

Author

H. Park

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Poly(ADP-ribose) Polymerase Inhibitor Talazoparib Inhibits DNA Damage Repair in Breast Cancer Cell Lines With or Without BRCA1/2 Mutation.

PURPOSE Talazoparib is a potent poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer. Although PARP inhibitor sensitivity has traditionally been attributed to synthetic letha...

Miso Lee, Kyung-Hun Lee, Ahrum Min et al. · 0 citations
Review Sep 2026

Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab-based chemoimmunotherapy in early triple-negative breast cancer and its clinical significance.

AIMS To characterize the heterogeneity of pathological responses in the breast and regional lymph nodes after neoadjuvant pembrolizumab-based chemoimmunotherapy in early-stage triple-negative breast cancer (TNBC) and to explore their clinical implications. METHODS AND RESULTS A total of 203 patients with TNBC treated...

Jiwon Koh, K. J. Suh, H. Park et al. · 0 citations
#artificial intelligence Review Sep 2026

BioEVAL: A global, multi-institutional benchmark of large language and multimodal models for bioengineering

Diverse cloud-scale foundation/multimodal models and locally deployable models suitable for inference on consumer-grade GPUs are evaluated, achieving the highest accuracy of up to 90% on MCQs, similarity score of 0.72 on literature synthesis, and accuracy of 80% on a small sample of multimodal reasoning questions, with...

Shun Ye, V. C. Suja, Chen-Long Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.